<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908709</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00106849</org_study_id>
    <secondary_id>NCI-2018-02065</secondary_id>
    <secondary_id>IRB00106849</secondary_id>
    <secondary_id>RAD4500-18</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT04908709</nct_id>
  </id_info>
  <brief_title>Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors</brief_title>
  <official_title>Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton&#xD;
      therapy works in assessing metabolic change in pediatric patients with brain tumors. The&#xD;
      non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor&#xD;
      metabolism compared to healthy tissue without injection of any contrast agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To obtain spectroscopic (s)MRI data from pediatric high grade glioma (HGG) patients before&#xD;
      receiving standard of care radiation therapy (RT) and correlate baseline Cho/NAA ratios to&#xD;
      recurrence patterns. (Cohort 1, observational) II. To assess the feasibility and safety of&#xD;
      using sMRI to define proton therapy high dose (60Gy) target volumes for treatment delivery.&#xD;
      (Cohort 2, intervention)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate how Cho/NAA defined radiation target volumes compare to standard of care&#xD;
      radiation target volumes in size and resulting radiation delivery to adjacent normal tissue,&#xD;
      by creating mock comparison RT plans for each patient.&#xD;
&#xD;
      II. To compare voxel-to-voxel changes in pre-treatment and post-treatment sMRI and evaluate&#xD;
      as potential early predictor of tumor response/recurrence.&#xD;
&#xD;
      III. To evaluate sMRI as a tool in identifying pseudoprogression vs. true progression and&#xD;
      correlate post-treatment sMRI metabolite ratios with histopathology if collected.&#xD;
&#xD;
      IV. To report patterns of failure in relationship to the RT field (local, marginal, or&#xD;
      distant), progression-free survival (PFS) and overall survival (OS) among all patients.&#xD;
&#xD;
      V. To report patient reported outcomes of health related quality of life (QOL) during and&#xD;
      after proton therapy for pediatric HGG.&#xD;
&#xD;
      VI. To build a longitudinal tracking database including clinical data, imaging, and genomic&#xD;
      molecular profiling for pediatric HGG treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo sMRI prior to radiation therapy, at 1, 4, and 7 months after RT, and at the&#xD;
      time of suspected recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">October 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cho/NAA ratios at baseline in tumor and in regions of tumor recurrence in patients receiving standard of care radiotherapy</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The spatial relationship between baseline sMRI abnormalities and tumor recurrence will be reported and proportion of overlap will be quantified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Toxicity will be defined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of using sMRI to define proton therapy high dose (60Gy) target volumes for treatment delivery</measure>
    <time_frame>From Baseline up to 3 years from treatment</time_frame>
    <description>Will be estimated by the Kaplan-Meier Method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Malignant Brain Glioma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (sMRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and/or at any time of suspected tumor recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopic Imaging</intervention_name>
    <description>Undergo sMRI</description>
    <arm_group_label>Diagnostic (sMRI)</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>1H- Nuclear Magnetic Resonance Spectroscopic Imaging</other_name>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>MRS</other_name>
    <other_name>MRS Imaging</other_name>
    <other_name>MRSI</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
    <description>Target volume treatment</description>
    <arm_group_label>Diagnostic (sMRI)</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Spectroscopic MRI</other_name>
    <other_name>Proton Radiation Therapy</other_name>
    <other_name>sMRI imaging</other_name>
    <other_name>Magnetic Resonance Spectroscopy</other_name>
    <other_name>3D whole brain MR spectroscopic imaging sequence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically diagnosed high-grade glioma (World Health Organization [WHO] grade&#xD;
             3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to&#xD;
             pathologic confirmation, but would be removed from study if pathology did not confirm&#xD;
             the diagnosis of high-grade glioma.&#xD;
&#xD;
          -  Primary tumor located within the supratentorial brain.&#xD;
&#xD;
          -  Recommended to receive definitive radiation therapy.&#xD;
&#xD;
          -  Able to receive MRI scans.&#xD;
&#xD;
          -  Both males and females, and members of all races and ethnic groups are eligible for&#xD;
             this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear&#xD;
             implants, non-titanium metal in ocular structures, or other incompatible implants&#xD;
             which makes MRI safety an issue are excluded.&#xD;
&#xD;
          -  Patients that have any significant medical illnesses that in the investigator's&#xD;
             opinion cannot be adequately tolerate MRI scan are excluded.&#xD;
&#xD;
          -  Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bree R Eaton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital/Winship Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bree Eaton, MD</last_name>
    <phone>404-778-3473</phone>
    <email>brupper@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Proton Therapy Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ardith R. DeShay</last_name>
      <phone>404-251-0753</phone>
      <email>adeshay@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Bree R. Eaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Scottish Rite</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Lomba</last_name>
      <phone>404-785-4803</phone>
      <email>christina.lomba@choa.org</email>
    </contact>
    <investigator>
      <last_name>Bree R. Eaton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillary Gaines</last_name>
      <email>hillary.gaines@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Bree R. Eaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Bree Eaton</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

